Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$7.77
−$0.12 · -1.52%
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Regular session
$7.77
−$0.12 · -1.52%
Regular session · ET · Market data may be delayed.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Day range
Current $7.77
52-week range
Current $7.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
87
Deep Value
Sentiment
54
Mixed
Risk
33
Moderate Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Day range
Current $7.77
52-week range
Current $7.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 180.46M USD | 160.95M USD | 142.52M USD | 129.34M USD | 103.64M USD |
| Cost of goods sold | 104.05M USD | 90.99M USD | 87.03M USD | 82.64M USD | 73.31M USD |
| Gross profit | 76.41M USD | 69.97M USD | 55.49M USD | 46.7M USD | 30.33M USD |
| Research and development | 13M USD | 15.19M USD | 13.93M USD | 13.17M USD | 11.36M USD |
| Selling, general, and administrative | 33.84M USD | 30.83M USD | 27.45M USD | 25.06M USD | 17.55M USD |
| Operating expenses | 50.17M USD | 49.92M USD | 45.43M USD | 42.17M USD | 31.02M USD |
| Interest income | 1.92M USD | 2.12M USD | 588K USD | 91K USD | 295K USD |
| Interest expense | 864K USD | 660K USD | 1.3M USD | 914K USD | 283K USD |
| Depreciation and amortization | 14.92M USD | 13.81M USD | 12.71M USD | 12.16M USD | 5.61M USD |
| Operating income | 26.23M USD | 20.05M USD | 10.06M USD | 4.53M USD | −696K USD |
| Net income | 20.2M USD | 14.46M USD | 8.28M USD | −2.32M USD | −2.23M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.00
93.05% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 27, 2026 | $0.17Semi-Annual | Aug 27, 2026 | Sep 17, 2026 |
Dividend | Mar 23, 2026 | $0.25Irregular | Mar 23, 2026 | Apr 7, 2026 |
Dividend | Mar 17, 2025 | $0.1998Special | Mar 17, 2025 | Apr 7, 2025 |
Ex-dividend Aug 27, 2026
$0.17
Semi-Annual
Record Aug 27, 2026 · Payment Sep 17, 2026
Ex-dividend Mar 23, 2026
$0.25
Irregular
Record Mar 23, 2026 · Payment Apr 7, 2026
Ex-dividend Mar 17, 2025
$0.1998
Special
Record Mar 17, 2025 · Payment Apr 7, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - International Small Cap Value ETFDISV381.38K0.01%5.07B USD0.42%$42.335-0.69%
Dimensional - International Small Cap ETFDFIS328.48K0.01%5.74B USD0.39%$35.64-0.50%
Dimensional - International Core Equity 2 ETFDFIC282.48K0.00%15.01B USD0.22%$37.24-0.27%
Acuitas Small Cap Active ETFAIMS190.85K0.23%83.63M USD0.75%$26.87-0.39%
Dimensional World ex U.S. Core Equity 2 ETFDFAX104.46K0.00%12.37B USD0.28%$36.785-0.80%
Invesco Nasdaq Biotechnology ETFIBBQ34.52K0.03%109.17M USD0.19%$33.52-1.44%
ProShares Ultra Nasdaq BiotechnologyBIB16.03K0.02%90.28M USD1.19%$104.36-2.89%Dimensional - International Small Cap Value ETFDISVDimensional - International Small Cap ETFDFISDimensional - International Core Equity 2 ETFDFICAcuitas Small Cap Active ETFAIMSDimensional World ex U.S. Core Equity 2 ETFDFAXInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
